Impax Opens New Front In Adderall Battle With Shire

Law360, New York (November 11, 2005, 12:00 AM EST) -- Impax Laboratories Inc. is taking action against the newest patent issued for anti-depressant Adderall XR, countersuing Shire Laboratories Inc. in federal court. At the same time, Shire is lobbying the FDA to further restrict the generic manufacture of the drug.

California-based Impax is seeking a declaratory judgment that it does not infringe Maryland-based Shire’s Adderall patent and that the patent’s claims are invalid. The suit was filed in the U.S. District Court for the District of Delaware.